[1]EuropeanJournalofMedicinalChemistry,2017,vol.130,p.286-307
[2]BioorganicandMedicinalChemistry,2009,vol.17,#5,p.2077-2090
[3]JournalofChemicalResearch,2018,vol.42,#5,p.244-246
[1]MedicinalChemistry,2013,vol.9,#5,p.681-688
[1]JournaloftheChemicalSociety,PerkinTransactions2:PhysicalOrganicChemistry(1972-1999),1984,#4,p.615-620
[1]JournaloftheChemicalSociety.PerkintransactionsII,1984,p.615-620
[1]JournaloftheChemicalSociety.PerkintransactionsII,1984,p.615-620
[1]LettersinOrganicChemistry,2019,vol.16,p.600-605
[2]EuropeanJournalofMedicinalChemistry,2017,vol.130,p.286-307
[3]BioorganicandMedicinalChemistry,2009,vol.17,p.2077-2090
[4]JournalofChemicalResearch,2018,vol.42,p.244-246
[1]NatureChemistry,2010,vol.2,p.735-740
[1]TetrahedronLetters,2012,vol.53,p.2336-2340
Title: Torsten K, et, al. Synthesis and radiopharmacological investigation of 3-'-[(18)Ffluorobenzylideneindolin-2-one as possible tyrosine kinase inhibitor. Bioorg Med Chem. 2009 Nov 15; 17(22): 7732-42.